Epilepsy-associated malformations of cortical development (MCDs) comprise a variety of dysplastic and neoplastic lesions of yet undetermined molecular pathology. Histopathologic similarities between MCDs and dysplastic brain lesions in the autosomal inherited neurocutaneous phacomatosis tuberous sclerosis (TSC), which affects the TSC1 and/or TSC2 genes, suggest common pathogenetic mechanisms. Previous studies revealed different alterations of TSC1 and TSC2 in epilepsy-associated malformations and glio-neuronal tumors despite histopathologic similarities. In order to examine current clinico-pathologic classification systems of cortical malformations on the molecular level, we carried out a mutational analysis of TSC1 and TSC2 in a series of surgical specimens obtained from patients with FCD without Taylor type balloon cells (FCD IIa ; n = 20), architectural dysplasias (FCD I ; n = 15), nodular cortical heterotopias (NCH; n = 4), and heterotopic white matter neurons (WMNH; n = 19). In FCD IIa , abundant genomic polymorphisms were detected in TSC2 (intron 4) but no allelic variants observed in exon 17 of TSC1. This allelic distribution pattern is in contrast to findings in FCD I and WMNH but also to those previously reported in FCD IIb (Taylor's balloon cell type). The latter revealed increased frequencies of specific alleles only in TSC1. The determination of characteristic molecular genetic alterations in specific epilepsy-associated malformations will support a comprehensive clinico-pathologic classification system and help to identify molecular pathways with potential pathogenetic relevance.
INTRODUCTION
Circumscribed malformative lesions of the central nervous system are frequently associated with drug-refractory epilepsies and comprise a wide spectrum of neuroradiologic and histomorphologic alterations (1) (2) (3) (4) (5) (6) . Epilepsy surgery has become an important treatment option in many of these patients and access to surgical brain specimens allows a systematic characterization of the histomorphologic lesion. Glio-neuronal lesions, including malformations of cortical development (MCD) and neoplasms such as gangliogliomas, are frequent histopathologic findings (7) . These entities share a highly differentiated glio-neuronal architecture and benign biologic behavior (2, 8, 9) . The group of MCDs is clinically as well as histologically diverse, ranging from subtle architectural aberrations to obvious cytologic and structural dysplasias. Current classifications on MCDs are based on histologic characteristics including loss of cortical lamination, glio-neuronal and/or neuronal heterotopias, the presence of dysplastic or cytomegalic neurons and Taylor-type balloon cells (2, 4, 10) . Although MCDs are related to compromised neuronal migration and differentiation of neuronal precursors during cortical development (11) (12) (13) , their pathogenetic relationship and molecular genetic basis remain to be determined (14) .
Recent clinico-pathologic studies point to a role of genes and pathways in these sporadic lesions (15) (16) (17) , otherwise associated with rare familial disorders such as tuberous sclerosis (TSC) (18, 19) . TSC is caused by germline mutations of the TSC1 (hamartin) and TSC2 (tuberin) genes on chromosomes 9q and 16p, respectively (20) (21) (22) . However, epilepsy patients with gangliogliomas or focal cortical dysplasias (FCDs) do not usually present with additional TSC-associated stigmata such as facial angiofibromata or angiomyolipoma of the kidney (23) . Hamartin and tuberin form a tumor suppressor complex and play a central role in the phosphatidylinositol 3-kinase (PI3K)/mTOR pathway, affecting morphogenesis, cell adhesion/migration, and cell fate determination (15, 24, 25) . Alterations within this signal transduction cascade would thus be compatible with dysplastic lesions of the neocortex and presence of balloon cells, i.e. FCD IIb (15) . Interestingly, about 66% of FCD IIb lesions carry altered allelic variants of TSC1 or loss of heterozygosity (LOH) of the TSC1 locus (17, 26) . The TSC genes also play a role in benign neoplasms, such as subependymal giant cell astrocytomas. In addition, distinct allelic distribution patterns within the TSC2 gene can be identified in the majority of gangliogliomas (26, 27) , which share striking histopathologic similarities with cortical tubers or FCD. However, neoplastic transformation appears rather to affect the glial than the neuronal cell component in this peculiar tumor entity (28, 29) .
The spectrum of dysplastic and architectural alterations in FCD challenges any clinico-pathologic classification system. In contrast to FCD IIb , FCD IIa lack balloon cells but presents with a misshapen, dysplastic neuronal component characterized by aberrant orientation, enlarged cell size, and abnormal process arborization (Fig. 1) . Whereas FCD IIb are frequently localized outside the temporal lobe, FCD IIa and gangliogliomas share a predilection for temporal localization (2) . Milder forms of MCDs may be as well related to aberrant neuronal migration and differentiation. This holds true for white matter neuronal heterotopias (WMNH) and nodular cortical FIGURE 1. Representative malformations of cortical development associated with focal epilepsy. Epilepsy-associated lesions comprise a broad spectrum of histopathologic alterations within cortex and white matter. (A) Patient with histopathologically approved heterotopic white matter neurons. In most patients, coronal T2-weight and FLAIR MR images demonstrate a variable gray/white matter blurring in the anterior temporal lobe (black arrow; accompanying hippocampal Ammon's horn sclerosis is indicated by white arrow). Histopathologically, numerous heterotopic neurons are interspersed and partially aggregated in the white matter as shown by hematoxylin and eosin staining ( heterotopias (NCH) (Fig. 1) . However, ectopic neurons in the white matter represent a physiological hallmark of the temporal lobe (30) . In WMNH associated with pharmacoresistant epilepsy, the abundance of heterotopic neurons in white matter is substantially increased (30, 31) and small clusters of white matter neurons are observed. In contrast, NCH contain coherent cortical islands in the white matter. In these cortical areas, a regular cortical lamination is missing. FCD I is characterized by cortical dyslamination (Fig. 1) , abundant microcolumnar architecture, and solitary giant or immature but not dysplastic neurons (2, 32) . Nevertheless, ectopic neurons in white matter can also be observed in these specimens. It remains to be shown, therefore, whether distinct pathogenetic mechanisms operate in individual subgroups of FCDs. Previous findings indicated a high incidence of TSC1 polymorphisms in FCD IIb (17) , which prompted us to extend this molecular genetic approach to distinct malformative entities of the neocortex in epilepsy patients by carrying out systematic mutational analyses of the TSC1 and TSC2 genes.
MATERIALS AND METHODS

Surgical Specimens
Biopsy samples were obtained from patients with chronic pharmaco-resistant epilepsy who were surgically treated in the Epilepsy Surgery Programs at the University of Bonn Medical Center (n = 31), Erlangen/Vogtareuth (n = 17), Germany; the Niguarda Hospital, Milano, Italy (n = 8); and the Gilead Hospital, Bielefeld-Bethel, Germany (n = 2). In each patient, surgical removal of the epileptogenic focus was mandatory to achieve seizure control according to established guidelines described in detail before (33, 34) . All participants gave informed and written consent and all procedures were conducted in accordance with the Declaration of Helsinki and approved by the local ethics committees of the individual institutions. Surgical specimens were fixed in formaldehyde overnight and embedded into paraffin. Specimens were subjected to a detailed macroscopic and histopathologic examination by experienced neuropathologists involving the Neuropathologic Reference Center for Epilepsy Surgery at the University of Erlangen, Germany (www.epilepsie-register.de).
Specimens were categorized according to an established classification system (2). Only those specimens in which neuropathologic examination allowed a clear classification as NCH, WMNH, FCD I , or FCD IIa groups were included in this study. None of the entities were classified as dual pathology. Particular care was paid to avoid confusion between FCD IIa and FCD IIb cohorts by histopathologic examination of multiple areas of the surgical specimen. FCD I cases were obtained from a unique series of young children with severe epilepsies, mental/psychomotor retardation, and multilobar ictogenesis (32) . Abnormal cortical architecture with abundant microcolumnar arrangements separated this group from WMNH, which were obtained from a series of adolescent patients suffering from temporal lobe epilepsies (Fig. 1 ). The number of solitary neurons within temporal lobe white matter sites was microscopically assessed in these specimens and exceeded 15 neurons per mm 2 , a value considered as uppermost margin of the physiological range (32) .
DNA Isolation
Starting from paraffin embedded tissue sections, areas comprising the malformative lesions were microdissected by avoiding adjacent normal CNS tissue (10 sections, 10 mm each) and subsequently subjected to DNA isolation. Regional accuracy was obtained by microscopic inspection of an adjacent section stained for hematoxylin and eosin (H&E). DNA extraction was performed using the QIAamp DNA MiniKit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Leukocyte DNA obtained from 100 unaffected Caucasians with no history of epilepsy or other known CNS diseases served as control and was isolated using a standard protocol as described elsewhere (35) .
PCR, Single Strand Conformation Polymorphism, and Sequencing Analyses
PCRs for TSC1 and TSC2 were carried out in an automated thermocycler (Uno Block, Biometra, Goettingen Germany) as previously described in detail (17, 26) . Briefly, in a total reaction volume of 10 ml, amplification was performed using 0.5 mM of each oligonucleotide primer, 200 mM of each dNTP, 50 mM KCl, 10 mM TRIS-HCl pH 8.5, 0.025 U Taq DNA polymerase system (Invitrogen, Karlsruhe, Germany), and 10 ng DNA template. PCR was carried out as follows: initial denaturation at 94°C for 5 minutes, 32 amplification cycles at 94°C for 30 seconds, a primer-specific annealing temperature for 40 seconds, an extension step at 72°C for 50 seconds, followed by a terminal elongation step at 72°C for 10 minutes. PCR products were electrophoresed on 2 to 3% agarose gels, and visualized by ethidium bromide staining. Primer combinations were used as reported previously (17, 26) . The PCR amplification products were subjected to single strand conformation polymorphism (SSCP) analysis. We examined up to 6 different electrophoresis conditions varying the polyacrylamide gel (PAG) concentrations and the acrylamidebisacrylamide ratios as follows: 14% PAG with a 99:1 ratio, 10% PAG with a 49:1 ratio, and 10% PAG with a 29:1 ratio. In each condition glycerol (5%) was added optionally. All PAGs were run at room temperature or 4°C using a voltage of 60 V (36) . SSCP variants as well as corresponding wild type samples were selected for direct sequencing of the PCR products (Fig. 2) . Sequencing was performed using an ABI PRISM 373A DNA sequencer (Applied Biosystems, Perkin-Elmer, Weiterstadt, Germany) according to standard protocols described previously (26) .
Laser Capture Microdissection
For isolation of heterotopic, malformative and/or dysplastic neuronal elements, as well as adjacent normal CNS tissue/vasculature components as controls, UV-Laser microbeam technology based on a nitrogen laser (PALM, Bernried Germany) was used in order to microdissect and subsequently harvest individual cellular elements (37) . Pathological elements could be clearly differentiated according to their heterotopic localization, nuclear and cellular dysplastic morphologies after hematoxylin and eosin staining, and/or Nissl-staining of 10 mm q 2005 American Association of Neuropathologists, Inc.
paraffin sections (Fig. 2) . Representative cells were harvested and sampled for each PCR reaction for subsequent use in polymorphism/LOH analyses. Cells from normal cortex as well as vessel components of the same patient outside the malformative lesion served as controls. Harvested samples were further processed as described before (17, 26) . The DNA isolation was carried out using the QIAamp DNA Mini Kit according to the manufacturer's guidelines (Qiagen).
Loss of Heterozygosity Analysis
Examination of LOH status at the TSC1 locus on 9q was realized as described before (17) . A total reaction volume of 10 ml containing 10 to 50 ng of DNA, 200 mM of each dNTP, 0.025 U Taq polymerase, 50 mM KCl, 10 mM TRIS-HCl pH 8.5, 1.5 mM MgCl 2 , 0.01% gelatin, and 0.5 mM of each primer was used. Primer combinations were used for microsatellite markers D9S302 (9q), D9S303 (9q), D9S319 (9cen), and D9S741 (9p) as reported previously (17) . Amplification was performed in an automated thermocycler (Uno Block, Biometra) for 32 cycles at 94°C for 30 seconds, annealing for 40 seconds at 55°C, and 72°C for 50 seconds. Reactions were carried out at least twice. PCR products were separated on denaturing gels (12% polyacrylamide, 5% glycerol, 13 TBE buffer) by electrophoresis (20 W, 15°C) and visualized by a silver staining procedure (36) .
Statistical Analysis
Differences of allele frequencies between pathologic specimens and controls were tested by Pearson's 2-sided x 2 test. Cutoff was set 2-sided p # 0.05 for p values to be significant.
RESULTS
Malformations of cortical development were obtained from 58 patients with drug-refractory epilepsy and screened for sequence alterations of the TSC1 and TSC2 genes by SSCP analysis. The lesions included in the present study comprised mild malformations, that is, neuronal WMNH (n = 19) and NCH (n = 4), as well as focal cortical dysplasias subclassified as FCD I and FCD IIa ( Fig. 1 ; Table 1A ). Somatic mutations were not identified in this series of cortical malformations. All sequence alterations encountered have been previously described as polymorphisms and were detected either in gangliogliomas and/or FCD IIb (17, 21, 26, 27) .
In our series of 20 FCD IIa cases, 2 previously described polymorphisms in the TSC1 gene were observed (38, 39) (Table 1B; Fig. 3 ). One polymorphism was found in 3 FCD IIa patients within the PCR fragment spanning intron 13/exon 14. It represented a combination of a silent base exchange (AG) at position 1556 (Glu, codon 445) and a noncoding base exchange (CG) at position 1555-55 in intron 13 (GenBank AF013168). The allele frequency of 7.5% was not significantly increased in FCD IIa compared to controls (also 7.5%). Another previously described nucleotide polymorphism was found in exon 22 (17, 38) , that is, a silent CT base transition at nucleotide 3050 (Ala, codon 943). The allele frequency of this alteration was 12.5% both in FCD IIa and in controls. In contrast to FCD IIa specimens, we found the polymorphism in intron 13/exon 14 to be significantly increased in WMNH and FCD I . The coding polymorphism affecting the interaction domain between hamartin and tuberin (exon 17 of TSC1), which is significantly increased in FCD IIb specimens (17), was not recognized in the present series of cortical malformations.
Rare TSC2 alleles were recognized in FCD IIa , which appear also to accumulate in gangliogliomas. This holds true for a polymorphism in intron 4 (26, 27) (Table 1B) , which encodes a CT exchange at nucleotide 174 (GenBank L48521) (26, 27) . In 2 FCD IIa patients, a complex cluster of noncoding base pair changes was observed in intron 30, previously described in gangliogliomas as well as FCD IIb (17, 26) . Additional polymorphisms were found in intron 31/exon 32 (n = 2) (GenBank L48540: 257 GA; GenBank L48521: 3933 GA, silent) (allele frequencies: 5.0% in FCD IIa vs. 5.5% in controls) and exon 40 (n = 5) (GenBank L48521: 5220 TC, silent) previously described in gangliogliomas (26) .
In the WMNH, NCH and FCD I groups we observed polymorphisms in exons 10 and 41 of the TSC2 gene (Table 1A) . The polymorphism in exon 10 is characterized by a base exchange from G to A (GenBank L48521: 1118, codon change 367 R . Q) in combination with an A to G transition (GenBank L48521: 1128, silent) (26, 38, 40, 41) . Another silent exonic polymorphism was found in exon 41 (n = 6) (GenBank L48521: 5346 GC). However, none of these additional polymorphisms was significantly increased compared to controls.
Further analysis addressed LOH and microsatellite instability (MSI) at the genomic TSC1 locus, previously described in FCD IIb patients (17, 42) . DNA of 18 cortical malformations proved suitable for LOH analysis (Fig. 4) . According to established definitions of LOH/microsatellite instability (43) , combinations of LOH and MSI were found only in individual NCH as well as FCD IIa cases (Fig. 4) . In another FCD IIa , we have observed combined MSI in D9S303 and D9S319. However, in none of these cases, accompanying genomic sequence alterations of TSC1 were present. Vice versa, neither FCD I nor WMNH presented with significant LOH or MSI.
DISCUSSION
Molecular genetic analysis of TSC1 and TSC2 genes indicates a large allelic variability within cohorts of epilepsy patients suffering from MCDs, although no mutations are found in the coding areas of both genes. There is a significant increase of a polymorphism in intron 4 of TSC2 in FCD IIa (Fig. 3) , whereas intron 13/exon 14 of TSC1 contains a complex polymorphism particularly abundant in WMNH and FCD I . Similar allelic distribution patterns between entities may argue for common pathogenetic mechanisms and appear helpful to corroborate recently established clinico-pathologic classification systems (2-4). With respect to previous studies in gangliogliomas and FCD IIb , distinct patterns of polymorphisms and LOH/MSI at TSC1 and TSC2 loci can be observed in the present series of cortical malformations. Significantly increased genomic polymorphisms have been reported for TSC1 in FCD IIb (17) , whereas only TSC2 was affected in FCD IIa samples (Fig. 4) . We identified the coding polymorphism in exon 17 of TSC1 as most significant classifier between FCD IIb and FCD IIa patients. This polymorphism results in an exchange of a basic histidine by the neutral amino acid tyrosine and is located in the interaction domain with TSC2, suggesting a potentially compromised tumor suppressor function of the resulting protein (19) . With respect to the longstanding debate of ''lumping or splitting'' the set of described MCD entities, the present data support the concept that different pathogenetic events occur at least in FCDs with balloon cells (FCD IIb ) versus FCD without balloon cells (FCD IIa ). Clinical observations reporting a favorable postsurgical outcome in FCD IIb patients may further support this notion (8) .
In contrast, FCD I and WMNH share abundant polymorphisms in intron 13/exon 14 of TSC1 (Fig. 3) , which had been previously reported to be significantly increased in FCD IIb (17) . On the other hand, they differ from FCD IIb by lack of i) significantly increased frequencies of polymorphisms in exon 17 and 22 of TSC1, as well as ii) by not having a substantial number of LOH and/or MSI events at the TSC1 locus on 9q. Furthermore, FCD I and WMNH did not exhibit significant genomic sequence alterations of TSC2. Since the NCH samples under study did not reveal significant sequence alterations in TSC1 or TSC2, our data delineate different allelic variants in more subtle cortical malformations. The TSC1 polymorphism in intron 13/exon 14 is neither coding nor coupled with LOH of the second allele in FCD I or WMNH. The increased frequency of this polymorphism might be regarded, therefore, as molecular characteristic but does not point to a pathophysiological role of TSC1 in these histopathologically mild forms of MCDs. In contrast to our findings in FCD IIb , the above-mentioned coding polymorphism in exon 17 of TSC1 is neither present in the WMNH, NCH groups, nor in FCD I (17) . Considering the large spectrum of clinicopathologic entities to be described, molecular analysis of TSC1 and TSC2 alleles support the distinction between FCD type I, IIa, and IIb, as well as WMNH and NCH.
Gangliogliomas reveal a variety of genomic alterations affecting the TSC2 gene, including abundant complex and silent polymorphisms in exons 4, 40, and 41, respectively (26, 27) . The polymorphism in intron 4 of TSC2 as well as a cluster of polymorphisms in exons 30 and intron 31/exon 32 are also observed in our present series of FCD IIa samples (Fig. 3) . The mutation detected in intron 32 of laser microdissected glial tumor cells of a ganglioglioma (26) has not been found in the present series of MCDs. Although the patterns described here may be suggestive for a role of FCD IIa as potential dysplastic precursor lesion for gangliogliomas (28) , coexistence or transition of FCD IIa to gangliogliomas have been rarely described in biopsy specimens of pharmacoresistant patients with focal epilepsies (unpublished observation in 418 gangliogliomas, in which only 3 cases revealed distinct signs of cortical dysplasia; www.epilepsie-register.de; see also [7] ). LOH and MSI at the TSC1 locus are frequent findings in FCD IIb specimens and may play a pathophysiologic role for the development of these lesions (42) . Notwithstanding, the combination of TSC1 sequence alterations with LOH at the TSC1 locus was confirmed in the laser-microdissected balloon cell component of FCD IIb specimens only (17), which is not present in WMNH, NCH FCD I , or FCD IIa . In our series, we have analyzed chromosome 9q abnormalities in laser-microdissected regions with distinct pathologies obtained either from WMNH, NCH, FCD I , or FCD IIa samples. Neither of these experiments revealed a similar pattern with that observed in FCD IIb specimens. The admixture of dysplastic neurons and balloon cells is, therefore, not only histopathologically distinctive from FCD IIa and other MCDs, but also with respect to molecular alterations, that is, at the TSC1 locus. It may be reasonable to further conclude that balloon cells represent a specific cell population and are not precursor cells, which sporadically differentiate into glia or dysplastic neurons.
The TSC1/TSC2 complex plays an important role during cortical development and growth control (25) . Tuberin and hamartin form a functional complex that is located downstream of Akt and inhibits mTOR signaling by acting as a GTPase-activating protein for small molecular weight-GTPase Rap1 (Rap1Gap) (44) . At distinct stages of CNS development, a precise interaction of tuberin and hamartin appears critical. Whether this pathway plays a pathophysiologic role in WMNH and NCH remains to be further determined. We have observed, however, a genomic coding polymorphism in exon 10 in TSC2 only in a NCH and FCD I sample.
In conclusion, the present data reveal distinct patterns of TSC1 and TSC2 allelic variants in FCD IIa , FCD I , and neuronal heterotopias. These molecular findings support current clinico-pathologic classification systems of epilepsyassociated lesions presenting with or without dysplastic neuronal components on the molecular level. Lesions lacking dysplastic neurons (i.e. WMNH and FCD I ) reveal increased FIGURE 3 . Sequence alterations of the TSC1 and TSC2 genes in patients with FCDIIa. Sequence alterations of TSC1 in intron 13/exon14 as well as exons 17 and 22, which have been found as significantly increased in FCDIIb, were not accumulated in FCDIIa (gray inserts contain sequence alterations previously found for FCDIIb in TSC1 as well as gangliogliomas in TSC2; x 2 : *, p , 0.05). This finding suggests different molecular alteration patterns with respect to TSC1 and TSC2 in FCDIIa versus FCDIIb. A nucleotide exchange in TSC2 intron 4 previously found to be accumulated in gangliogliomas is also significantly increased in FCDIIa. The mutation previously reported in a ganglioglioma was not found in the series of FCDIIa.
frequencies only for an intron 13/exon 14 polymorphism in TSC1. In contrast to FCD IIb , no accumulation of LOH or MSI events was present at this locus. FCD IIa , harboring dysplastic neuronal components, showed increased genomic alterations in TSC2, a pattern substantially different from FCD IIb . The correlation between clinical, imaging, neuropathologic, and molecular analyses may help to further develop comprehensive classification systems and treatment strategies in patients suffering from MCDs. 
